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The Centers for Disease Control and
Prevention currently estimate the preva-
lence of Autism Spectrum Disorder (ASD)
in the U.S. at 1:68 children (Baio, 2014).
Despite decades of research across mul-
tiple levels of analysis, we currently lack
a reliable biomarker that may facilitate
diagnosis, illuminate pathophysiology,
or guide treatment. The development
of novel treatment strategies for ASD
will require efforts for better clinical
characterization, identiﬁcation of more
homogeneous subgroups for studies,
and improved understanding of under-
lying pathophysiology. There is growing
support for early intensive interven-
tions in this population (Reichow, 2012).
Pharmacological treatments have been
s h o w nt ob ee f f e c t i v ei nt r e a t i n gs o m e
of the common secondary and comorbid
features of ASD (Hampson et al., 2012),
but there is currently no pharmacotherapy
conclusively shown to improve the core
symptoms (Oberman, 2012).
Recently a number of investigators have
begun to explore the use of transcra-
nial magnetic stimulation (TMS) as a
tool to characterize ASD pathophysiol-
ogy, and to test its therapeutic potential.
TMS is a safe and well-tolerated method
for non-invasive focal cortical stimulation
where small intracranial electrical cur-
rents are generated by a rapidly ﬂuctuating
extracranial magnetic ﬁeld. In an effort to
share recent progress in the use of TMS in
ASD,promotecollaborationacrosslabora-
tories, and establish consensus on param-
eters that may be useful for the study of
pathophysiology and the potential treat-
ment of ASD, leading experts in the
ﬁeld gathered in Atlanta, GA on May
13th and 14th 2014 for the “Transcranial
Magnetic Stimulation (TMS) Therapy
for Autism Consensus Conference” orga-
nized and supported by the Clearly
Present Foundation with additional sup-
port from Neuronetics, Inc. and Autism
Speaks.
AlvaroPascual-Leonebegantheconfer-
ence by discussing the basic mechanisms
and safety of TMS in clinical populations.
T M Sc a nb ea p p l i e di ns i n g l ep u l s e st o
investigate corticospinal excitability, pairs
of pulses to study intracortical inhibi-
tion and facilitation, and repeated trains
of TMS (rTMS) to both to study and
therapeutically modulate excitability and
plasticity in a number of neurologi-
cal and psychiatric conditions (Kobayashi
and Pascual-Leone, 2003). The effects of
rTMS can be expected to differ consid-
erably by virtue of varying parameters of
stimulation and knowledge of underlying
symptompathophysiology.TMSisconsid-
ered quite safe if applied within current
safety guidelines; however, it does pose
some risk for adverse side-effects (Rossi
etal.,2009).Thoughrelativelyfewpatients
with ASD have participated in TMS pro-
tocols, the frequency and quality of side-
effects shown thus far approximates that
seen in the general population (Oberman
et al., 2013). As with any other condition,
factors including medications and medical
history need to be assessed when deter-
mining risk for an individual. There are
currently no identiﬁed ASD-speciﬁc risk
factors for TMS-induced adverse effects.
Even though ASD can be associated with
an increased risk for seizures, in TMS
s t u d i e st od a t e ,t h e r ei sn oe v i d e n c eo f
increased epileptogenic risk in ASD when
safety guidelines and recommendations
are followed.
Manuel Casanova then provided a tar-
geted review of the literature on the patho-
physiology of ASD. Postmortem studies
have shown evidence of abnormalities of
neuronal migration in the brains of indi-
viduals with ASD (Bailey et al., 1998),
whichincludedisplacedneuronsmanifest-
ing as focal cortical dysplasias in a major-
ity of individuals with ASD (Casanova
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et al., 2013). Morphometric analysis of
cells within the malformed cortex has sug-
gested a reduced number of interneurons
(Casanova et al., 2013). This is consistent
with previous reports of abnormalities in
ASD within the peripheral cortical mini-
column neuropil space, the compartment
where most inhibitory cells are located
(Casanova et al., 2002). Both EEG and
vibrotactile studies corroborate a deﬁcit
of cortical lateral inhibition (Keita et al.,
2011; Puts et al., 2014). He proposed that
this deﬁcit could account for the seizures
and sensory abnormalities often reported
in ASD.
Lindsay Oberman discussed the use
of TMS as an investigative device to
study cortical excitability and plasticity in
ASD. These studies show that a num-
ber of basic mechanisms and circuits are
atypical while other measures appear to
be normal (see Oberman et al., 2013).
Speciﬁcally, motor thresholds and base-
line motor-cortical excitability measures
appear to be normal. There is hetero-
geneity in the response to paired-pulse
paradigms with impaired inhibition in
some individuals, typical response in oth-
ers, and paradoxical facilitation in another
subgroup. Studies exploring corticospinal
plasticity mechanisms, using two differ-
ent rTMS protocols [theta burst stimula-
tion (TBS) and paired associative stimu-
lation (PAS)], have shown abnormalities.
However, the direction of the abnormal-
ity is unclear with TBS studies showing
enhanced response (Oberman et al., 2012)
and PAS showing reduced response (Jung
et al., 2013) .T h e r ea r ean u m b e ro fo p e n
questions related to the use of TMS as
an investigative device in ASD includ-
ing developmental effects, effects related
to intellectual disability and functioning,
andwhatunderlyingmechanismsaredriv-
ing the observed heterogeneity in the
population.
Peter Enticott discussed the efﬁcacy
of rTMS as a therapeutic intervention
in ASD. A number of studies using
low-frequency rTMS in an effort to
enhance cortical inhibitory tone in dor-
solateral prefrontal cortex have resulted
in improvements in EEG indices of
attention, information processing, and
error monitoring as well as behavioral
improvements in repetitive behaviors
and irritability (Sokhadze et al., 2014).
Low-frequency stimulation to left pars
triangularis resulted in improved object
naming in a single session study (Fecteau
et al., 2011). High-frequency stimula-
tion, designed to enhance excitability, has
suggested improvements in self-reported
social relating and social anxiety follow-
ing medial prefrontal cortex stimulation
(Enticott et al., 2014) and signiﬁcant
improvements in eye-hand coordina-
tion following premotor stimulation
(Panerai et al., 2013). Although an emerg-
ing literature, these studies collectively
provide support for the potential efﬁ-
cacy of rTMS in ASD (Oberman et al.,
2013). However, the small study samples,
lack of blind assessments, and limited
use of control or comparison conditions
limit the interpretation of these early
investigations.
James McCracken concluded the con-
ference by discussing key factors to con-
sider when designing clinical trials for
ASD. These factors included identiﬁcation
of valid and reliable endpoints, incorpora-
tion of blind assessments, need for cred-
ible control conditions, establishment of
effective stimulation parameters, need to
relate changes in electrophysiologic end-
points to functional change, and identi-
ﬁcation of biomarkers that can be used
to reduce the heterogeneity of the sam-
ple and stratify participants to treatment
strategies that are best matched to their
underlying pathophysiology. To this end,
thosepresentdiscussedtheutilityofdevel-
opingfunctionalimagingandTMSindices
as potential standardized biomarkers and
the need for larger, multisite trials to
establish validity of these measures across
development and levels of functioning
and reliability of these measures across
centers.
At the conclusion of the conference,
there was enthusiasm for the potential use
of TMS in ASD. Further work is nec-
essary to achieve consensus on the key
factors discussed by Dr. McCracken, but
the expertise and commitment is present
in the research and clinical community
to work toward the end goal of design-
ing and implementing large-scale, double
blind, multisite clinical trials of rTMS for
ASD in the near future. Those present
committed to collaborate across labora-
tories to establish mutually agreed upon
protocols and to meet again within 1 year.
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